SingMedical   

The Next Medical Stock to watch

https://stocknewsnow.com/commentary/ANEWSID16092015100002/AMWS-Rights-Exercised-Price-vs-Stock-Price

Further information in this article however I would answer no to your question.

 

now that the market price is 0.46, just wondering whether will people still exercise the right issue price of 0.48 ?

any bro has any view on this?
 

 

When ask my guru why result good share no run ? he said must have BB to play, no BB no play !!

 

A gem in the making.Major shareholders are driving the group and we can only expect positive results.Invest now and enjoy the ride.

 

i added at 0.50.  long term this should be very good investment.

 

Financials look strong. I would get in earlier. Price will start to rise again, once issue completed..

 

first let me subscribe to the rights.

 

Price has dropped by about 10% since before its proposed rights announcement.   
For those who believe in the company' s future, it will be a good time to buy/accummulate.
Most broking houses have target price higher than current value.

 

I think the dropping of price as a result of right issue already partly reflected in the recent drop from 0.60 to 0.55.

Those insider already taken the first round of sell down BEFORE the announcement of right issue.

 

Looking past their rights issue, share pricing going down etc.... Ask yourself this questions:
.
.
1. Is the company doing well? Is the balance sheet good?
2. Does the management has acute business sense (from what they are doing in the past till now, and in the future?
3. Moving forward, can their good performance and aggressive growth propel their share price to $80.00 or beyond may be in the next 2 years?
4. Are you willing to be in the game with the management?
5. Are you able to stomach the paper loss currently since we are forward looking?
6. Are you able to buy in more share if it is reasonably priced/ cheap after the exercise?
.
.
For me:
I see this as positive as management also wants us to be aligned with the company direction. Have some skin in the game as well.
I also bought above 0.60.
I will subscribe to excess rights.
i will buy in more shares if the time/ price is right.
I will hold.

 

theoretically if all newly issued shares are 100% subscribed at the given price at 0.48. the price traded after XR should be:

=(((453000000*0.55)+(23040500*0.48))/(453000000+23040500))
= $0.55

What about those who bought it before XR at may be $0.60/ share?
Should he be lowering his cost/ share by subscribing to excess right?
(note: may not get the no. of excess you wanted)

and there' s no guarantee that price might not go lower than $0.55 before CR.

selling the nil-paid rights and buy more shares in the market (after XR) may be a viable options.


Irrevocable Undertaking by SMG Directors/ CEO
____________________
The Substantial Shareholders or Directors of the company may give their support for the Rights Issue to demonstrate their commitment and confidence in the prospects of the Company. They will give their irrevocable undertakings to subscribe for the Right Shares which are not fully taken up by other shareholders. With the irrevocable undertakings by the Substantial Shareholders or Directors, the Company may then pursue a Rights Issue on a non-underwritten basis, thereby bringing about cost savings in the form of the underwriting fee.

 

They will send you the docs

 

Any idea when' s the right issue record date? Not released yet?

 

Prepare for price to go lower

 

Right issue for acquisition.

The share pattern will be like Koh Eco?

 

Right issue? How would market react?

 

Good result, 100% increase in gross profit, 200% increase in net profit.

 

 

anyone knows when will they be announcing their 2017 result?

 

http://www.businesstimes.com.sg/companies-markets/singapore-medical-group-takes-stake-in-australian-ivf-specialist

big news? 

 

Top Idea of the Day
Singapore Medical Group Ltd (SMG SP): BUY (Initiating
coverage)
Last Traded Price: S$0.60 Price Target: S$0.75 (Upside
25.0%)
Robust growth prognosis
 Initiate coverage with BUY and TP of S$0.75 on the
back of continued robust growth post a successful
turnaround
 Project net profit growth of 292%/32% on ramp-up in
diagnostics, recent acquisitions, and margin
improvements
 Further re-rating catalysts to come from acquisitions,
better operating performance and overseas ventures
 TP based on 25x FY18F/19F PE